microdosing semaglutide for inflammation – the Surprising New Anti-Fibrosis Drug Go Micro with the Noom

Stromal cell derived factor-1alpha protects stem cell derived insulin-producing cells from glucotoxicity under high glucose conditions in-vitro and ameliorates drug induced diabetes in rats

Very rapid early weight loss (first 12 weeks) is usually fluid loss from osmotic diuresis, not fat

The variability in trial durations, ranging from 3 to 12 weeks across the included studies, and differences in the number of titration steps for each drug may further influence the reported incidence of gastrointestinal adverse events, particularly for agents like tirzepatide, where nausea risk escalates with higher doses (e.g., OR = 4.36, 95% CI: 3.425.61 at 10 mg) (Liu et al., 2025)

4Use the Interactive Syringe for a visual reference of the resulting volume

Gerbild, H., Larsen, C

The approval of Wegovy in the U.S